2025年臨床腫瘤學下一代定序全球市場報告

預計未來幾年臨床腫瘤學下一代定序市場規模將快速成長。到 2029 年，這一數字將成長至 9.5 億美元，複合年成長率為 12.9%。預測期內的成長歸因於癌症發生率的增加、精準醫療、免疫腫瘤學和液態切片。預測期內的關鍵趨勢包括綜合基因組分析 (CGP)、免疫腫瘤學、腫瘤進化和異質性、人工智慧和機器學習。

預計全球癌症患者數量的增加將成為近期臨床腫瘤學次世代定序儀市場的成長要素。根據美國癌症協會的數據，2021年光是美國就通報了190萬例新發癌症病例和60萬例癌症相關死亡病例。全球最常見的癌症是肺癌、攝護腺癌、大腸癌和乳癌，佔所有新發癌症病例的43%。因此，預計全球癌症發生率的上升將推動需求，從而推動臨床腫瘤學下一代定序市場的成長。

癌症盛行率的上升預計將推動臨床腫瘤學次世代定序儀(NGS) 市場的成長。癌症是指一組以體內異常細胞不受控制地生長擴散為特徵的疾病。 NGS 在檢測癌症中的新型和罕見突變方面發揮關鍵作用，有助於更好地了解個別腫瘤的分子基礎。例如，2024年5月，美國政府機構國家癌症研究所報告稱，美國約有1810萬癌症倖存者。預計到 2032 年，這一數字將上升至 2,250 萬。到 2040 年，每年新增癌症病例數預計將達到 2,990 萬，癌症相關死亡人數將達到 1,530 萬人。因此，癌症盛行率的上升是推動臨床腫瘤學下一代定序市場擴張的主要因素。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球臨床腫瘤學次世代定序市場的 PESTEL 分析（政治、社會、技術、環境、法律、促進因素、限制因素）
• 最終用途產業分析
• 全球臨床腫瘤學下一代定序市場：成長率分析
• 全球臨床腫瘤學下一代定序市場表現：規模與成長，2019-2024
• 全球臨床腫瘤學下一代定序市場預測：規模與成長，2024-2029，2034
• 全球臨床腫瘤學下一代定序總目標市場（TAM）

第6章市場區隔

• 全球臨床腫瘤學下一代定序市場（按技術、性能和預測），2019-2024 年、2024-2029 年、2034 年
• 離子半導體序列
• 焦磷酸測序
• 複合序列
• 即時序列
• 連接定序
• 可逆染料終止序列
• 奈米孔定序
• 全球臨床腫瘤學次世代定序市場的應用、效能與預測，2019-2024 年、2024-2029 年、2034 年
• 篩檢
• 伴隨診斷
• 其他
• 全球臨床腫瘤學下一代定序市場（按最終用戶、性能和預測）2019-2024、2024-2029、2034
• 醫院檢查室
• 臨床研究所
• 診斷實驗室
• 全球臨床腫瘤學次世代定序市場：離子半導體定序細分（按類型、效能和預測），2019-2024 年、2024-2029 年、2034 年
• 離子質子系統
• 離子PGM系統
• ION S5 系統
• 其他
• 全球臨床腫瘤學下一代定序市場：焦磷酸測序定序細分市場（按類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
• 454焦磷酸測序
• 其他
• 全球臨床腫瘤學次世代定序市場：按類型、表現和預測的合成定序細分，2019-2024 年、2024-2029 年、2034 年
• Illumina定序技術
• SOLiD定序技術
• 其他
• 全球臨床腫瘤學下一代定序市場：即時定序細分（按類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
• PacBio RS II 系統
• 續集系統
• 其他
• 全球臨床腫瘤學次世代定序市場：連結定序細分（按類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
• 螺旋單分子定序
• 其他
• 全球臨床腫瘤學下一代定序市場：可逆染料終止定序細分（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
• Illumina HiSeq
• Illumina NextSeq
• 其他
• 全球臨床腫瘤學下一代定序市場：奈米孔定序細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
• 牛津奈米孔技術（MinION、GridION、PromethION）
• 其他

第7章 區域和國家分析

• 全球臨床腫瘤學次世代定序市場（按地區、績效及預測），2019-2024 年、2024-2029 年、2034 年
• 全球臨床腫瘤學下一代定序市場（依國家、地區、績效及預測）2019-2024、2024-2029、2034

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

• 臨床腫瘤學下一代定序市場：競爭格局
• 臨床腫瘤學次世代定序市場：公司簡介
  • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Agilent Technologies Inc.
• Pacific Biosciences of California Inc.
• Caris Life Sciences
• Paradigm Diagnostics
• GATC Biotech AG
• Macrogen Inc.
• DNASTAR Inc.
• Exosome Diagnostics Inc.
• Biomatters Ltd.
• Partek Inc.
• Foundation Medicine Inc.
• Becton Dickinson and Company（BD）
• Takara Bio Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029年臨床腫瘤學下一代定序市場：提供新機會的國家
• 2029年臨床腫瘤學次世代定序市場：細分市場帶來新機會
• 臨床腫瘤學下一代定序市場 2029：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第36章 附錄

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

The increasing number of cancer cases worldwide is expected to be a contributing factor to the growth of the clinical oncology next-generation sequencing market in the foreseeable future. In 2021, the USA alone reported 1.9 million new cancer cases and 0.6 million cancer-related deaths, according to data from the American Cancer Society. The most common cancer types globally include lung, prostate, colorectal, and breast cancer, accounting for 43% of all new cancer cases. Consequently, the rising global incidence of cancer is likely to drive demand and foster growth in the clinical oncology next-generation sequencing market.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Companies in the clinical oncology next-generation sequencing market are increasingly investing in workflow automation to enhance precision and reduce sample-to-sample variability. For example, Agilent automation solutions have developed an automated system that enables a higher number of parallel reactions, reduces sample processing time, increases the volume of processed samples, and minimizes variability between samples. Additionally, companies like Sophia Genetics are focusing on data-driven medicine and the automation of DNA sequencing to enhance diagnostic and treatment capabilities.

Major companies operating in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market competitiveness. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, ultimately contributing to improved patient care. For example, in June 2022, the Switzerland-based pharmaceutical company Roche unveiled the BenchMark ULTRA PLUS system, their state-of-the-art platform for tissue staining. This system provides clinicians with rapid and accurate test results, aiding in timely treatment decisions for patients.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
• 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
• 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
• Subsegments:
• 1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
• 2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
• 3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
• 4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
• 5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
• 6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
• 7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
• Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Clinical Oncology Next Generation Sequencing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Clinical Oncology Next Generation Sequencing Market Growth Rate Analysis
• 5.4. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM)

6. Clinical Oncology Next Generation Sequencing Market Segmentation

• 6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing
• Real Time Sequencing
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing
• 6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Screening
• Companion Diagnostics
• Other Diagnostics
• 6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories
• 6.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ion Proton System
• Ion PGM System
• Ion S5 System
• Other Ion Semiconductor Sequencing Technologies
• 6.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 454 Pyrosequencing
• Other Pyro-Sequencing Technologies
• 6.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Illumina Sequencing Technology
• SOLiD Sequencing Technology
• Other Synthesis Sequencing Technologies
• 6.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real-Time Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PacBio RS II System
• Sequel System
• Other Real-Time Sequencing Technologies
• 6.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Helicos Single Molecule Sequencing
• Other Ligation Sequencing Technologies
• 6.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Illumina HiSeq
• Illumina NextSeq
• Other Reversible Dye Termination Sequencing Technologies
• 6.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oxford Nanopore Technologies (MinION, GridION, PromethION)
• Other Nano-Pore Sequencing Technologies

7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

• 7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

• 8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market

• 9.1. China Clinical Oncology Next Generation Sequencing Market Overview
• 9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market

• 10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market

• 11.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
• 11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market

• 12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market

• 13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market

• 14.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
• 14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market

• 15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
• 15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market

• 16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market

• 17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market

• 18.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Clinical Oncology Next Generation Sequencing Market

• 19.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Clinical Oncology Next Generation Sequencing Market

• 20.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Clinical Oncology Next Generation Sequencing Market

• 21.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
• 21.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Clinical Oncology Next Generation Sequencing Market

• 22.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Clinical Oncology Next Generation Sequencing Market

• 23.1. North America Clinical Oncology Next Generation Sequencing Market Overview
• 23.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Clinical Oncology Next Generation Sequencing Market

• 24.1. USA Clinical Oncology Next Generation Sequencing Market Overview
• 24.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Clinical Oncology Next Generation Sequencing Market

• 25.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
• 25.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Clinical Oncology Next Generation Sequencing Market

• 26.1. South America Clinical Oncology Next Generation Sequencing Market Overview
• 26.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Clinical Oncology Next Generation Sequencing Market

• 27.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Clinical Oncology Next Generation Sequencing Market

• 28.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
• 28.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Clinical Oncology Next Generation Sequencing Market

• 29.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
• 29.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

• 30.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
• 30.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche Ltd.
• 31.2. PerkinElmer Inc.
• 31.3. Agilent Technologies Inc.
• 31.4. Pacific Biosciences of California Inc.
• 31.5. Caris Life Sciences
• 31.6. Paradigm Diagnostics
• 31.7. GATC Biotech AG
• 31.8. Macrogen Inc.
• 31.9. DNASTAR Inc.
• 31.10. Exosome Diagnostics Inc.
• 31.11. Biomatters Ltd.
• 31.12. Partek Inc.
• 31.13. Foundation Medicine Inc.
• 31.14. Becton Dickinson and Company (BD)
• 31.15. Takara Bio Inc.

32. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

34. Recent Developments In The Clinical Oncology Next Generation Sequencing Market

35. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

• 35.1 Clinical Oncology Next Generation Sequencing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Clinical Oncology Next Generation Sequencing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Clinical Oncology Next Generation Sequencing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer